Related Experiment Video
Updated: Aug 22, 2025
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
Published on: August 29, 2016
Surgical Metastasectomy for Visceral and Bone Prostate Cancer Metastases: A Mini-Review
Pawel Rajwa1, Takafumi Yanagisawa2, Manuel Gruber3
1Department of Urology, Medical University of Silesia, Zabrze, Poland; Department of Urology, Medical University of Vienna, Vienna, Austria.
Abstract:
Despite growing interest in metastasis-directed therapy (MDT) for prostate cancer (PCa), little is known regarding the feasibility and effectiveness of surgical metastasectomy for isolated lesions. We performed a narrative review of the available evidence supporting metastasectomy for M1b-c lesions in men diagnosed with oligometastatic or oligorecurrent PCa. The case series and case reports we identified indicate that surgical MDT is a safe and feasible treatment option for well-selected patients with a small number of PCa metastases diagnosed via molecular imaging. It is difficult to draw evidence-based conclusions regarding the survival benefit of metastasectomy; however, metastasectomy might lead to a prostate-specific antigen response and could potentially delay systemic therapy in patients with oligometastatic PCa. Prospective studies incorporating novel imaging are needed to better establish the role of metastasectomy for patients with metastatic PCa. PATIENT SUMMARY: We reviewed the evidence on surgical removal of prostate cancer lesions that have spread to the organs (eg, liver and lung) or bone, which are called metastases. Limited results show that this approach is feasible and has favorable outcomes in selected patients.
Insights
Surgical removal of limited prostate cancer metastases (MDT) appears safe and feasible for selected patients. While survival benefits require more study, this approach may improve PSA response and delay systemic treatments.
Area of Science:
- Oncology
- Urology
- Surgical Oncology
Background:
- Metastasis-directed therapy (MDT) for prostate cancer (PCa) is gaining interest.
- Evidence on surgical metastasectomy for isolated PCa lesions remains limited.
- Oligometastatic and oligorecurrent disease represent specific clinical scenarios.
Purpose of the Study:
- To review the available evidence on the feasibility and effectiveness of surgical metastasectomy for M1b-c prostate cancer lesions.
- To assess the role of surgical MDT in men with oligometastatic or oligorecurrent PCa.
Main Methods:
- Narrative review of case series and case reports.
- Focus on evidence supporting metastasectomy for M1b-c lesions.
- Inclusion of studies involving molecular imaging for diagnosis.
Main Results:
- Surgical MDT is a safe and feasible option for select patients with limited PCa metastases.
- Molecular imaging aids in the diagnosis of small metastatic lesions.
- Evidence for survival benefit is difficult to establish, but PSA response and delayed systemic therapy are potential outcomes.
Conclusions:
- Surgical metastasectomy is a viable treatment for carefully selected patients with oligometastatic prostate cancer.
- Further prospective studies with advanced imaging are necessary to confirm survival benefits.
- Metastasectomy may play a role in managing oligorecurrent or oligometastatic prostate cancer.
